CTNM vs TERN vs INVA vs ABBV vs MRK

For growth investors, Innoviva, Inc.

(INVA) is the stronger pick with 18. 5% revenue growth year-over-year, versus 1. 2% for Merck & Co. , Inc. (MRK). Innoviva, Inc. (INVA) offers the better valuation at 6. 9x trailing P/E (6. 4x forward), making it the more compelling value choice. Analysts rate Contineum Therapeutics, Inc. Class A Common Stock (CTNM) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Innoviva, Inc.

(INVA) is the cheapest at 6. 9x versus AbbVie Inc. at 96. 1x. On forward P/E, Innoviva, Inc. is actually cheaper at 6. 4x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Innoviva, Inc. wins at 0. 62x versus Merck & Co. , Inc. 's 1. 09x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Terns Pharmaceuticals, Inc.

(TERN) delivered a total return of +247. 2%, compared to -22. 9% for Contineum Therapeutics, Inc. Class A Common Stock (CTNM). Over 10 years, the gap is even starker: ABBV returned +362. 2% versus CTNM's -22. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Innoviva, Inc.

(INVA) is the lower-risk stock at 0. 06β versus Contineum Therapeutics, Inc. Class A Common Stock's 0. 59β — meaning CTNM is approximately 934% more volatile than INVA relative to the S&P 500. On balance sheet safety, Terns Pharmaceuticals, Inc. (TERN) carries a lower debt/equity ratio of 0% versus 96% for Merck & Co. , Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Innoviva, Inc.

(INVA) is pulling ahead at 18. 5% versus 1. 2% for Merck & Co. , Inc. (MRK). On earnings-per-share growth, the picture is similar: Innoviva, Inc. grew EPS 816. 7% year-over-year, compared to -33. 1% for Contineum Therapeutics, Inc. Class A Common Stock. Over a 3-year CAGR, INVA leads at 8. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Innoviva, Inc.

(INVA) is the more profitable company, earning 63. 8% net margin versus 0. 0% for Terns Pharmaceuticals, Inc. — meaning it keeps 63. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INVA leads at 38. 5% versus 0. 0% for TERN. At the gross margin level — before operating expenses — INVA leads at 72. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Innoviva, Inc. (INVA) is the more undervalued stock at a PEG of 0. 62x versus Merck & Co. , Inc. 's 1. 09x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Innoviva, Inc. (INVA) trades at 6. 4x forward P/E versus 23. 2x for Merck & Co. , Inc. — 16. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for INVA: 75. 9% to $40. 00.

In this comparison, ABBV (2.

9% yield), MRK (2. 7% yield) pay a dividend. CTNM, TERN, INVA do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, AbbVie Inc.

(ABBV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 14), 2. 9% yield, +362. 2% 10Y return). Both have compounded well over 10 years (ABBV: +362. 2%, CTNM: -22. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: CTNM is a small-cap quality compounder stock; TERN is a small-cap quality compounder stock; INVA is a small-cap high-growth stock; ABBV is a large-cap quality compounder stock; MRK is a large-cap deep-value stock. ABBV, MRK pay a dividend while CTNM, TERN, INVA do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.